Teva will acquire BXCL501 from BioXcel Therapeutics for $57.5 million plus contingent payments of up to $67.5 million. Teva had announced its bid through a court-supervised sale process in August. Shares were up around 1% in Oct. 27 midday trading.
Portfolio improvements from continued uptick of commercial branded drugs and launch of pipeline assets should bolster Teva's top and bottom lines for the next decade.
The majority of Teva's business lies in generic and off-patent branded drugs, which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply chain exert force.
|
Metric
|
TEVA
|
VTRS
|
SDZ
|
|---|---|---|---|
Price/Earnings (Normalized) | 16.88 | 7.43 | 48.28 |
Price/Book Value | 6.07 | 1.52 | 4.89 |
Price/Sales | 2.71 | 1.48 | 3.88 |
Price/Cash Flow | 15.62 | 7.63 | 39.93 |
|
Metric
|
TEVA
|
VTRS
|
SDZ
|
|---|---|---|---|
Quick Ratio | 0.46 | 0.82 | 0.50 |
Current Ratio | 0.88 | 1.58 | 1.05 |
Interest Coverage | 1.79 | −0.38 | 4.66 |
|
Metric
|
TEVA
|
VTRS
|
SDZ
|
|---|---|---|---|
Return on Assets (Normalized) | 6.68% | 7.94% | 7.69% |
Return on Equity (Normalized) | 35.32% | 19.79% | 18.79% |
Return on Invested Capital (Normalized) | 14.43% | 11.04% | 12.29% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|C&KVWcMn | LOCK|Vdzv | $70B | |||
| Haleon PLC ADR
HLN
| LOCK|QmT%?$y | LOCK|FX | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|#KLZ>%@ | LOCK|XqR | $32B | |||
| Viatris Inc
VTRS
| LOCK|@W#mT! | LOCK|x#& | $22B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|%^K%^#< | LOCK|^w | $11B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|zs | LOCK|rY | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|^t?R$# | LOCK|%M | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|WyZQfW | LOCK|CS!JD | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|<WHN@s% | LOCK|j%? | $2B |
United States